Implication of intracellular localization of transcriptional repressor PLZF in thyroid neoplasms

BMC Endocrine Disorders

Shin-ichi Taniguchi⁴  Kazuhiro Yamamoto²  Chiaki Shigemasa⁵  Masakazu Haneda⁶  Yumi Takiyama⁶  Akio Yoshida³  Kiyosuke Ishiguro¹  Hiroko Ohkura⁴  Tsuyoshi Ohkura²  Shoichiro Izawa²  Kazuhiko Matsuzawa⁴ 

[1]Department of Surgery, Division of Organ Regeneration Surgery, Tottori University Faculty of Medicine, 36-1 Nishi-cho, Yonago 683-8504, Japan

[2]Department of Molecular Medicine and Therapeutics, Division of Endocrinology and Metabolism, Tottori University Faculty of Medicine, 36-1 Nishi-cho, Yonago 683-8504, Japan

[3]Division of Regenerative Medicine and Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science, 86 Nishi-cho, Yonago 683-8503, Japan

[4]Department of Regional Medicine, Tottori University Faculty of Medicine, 86 Nishi-cho, Yonago 683-8503, Japan

[5]Tottori Municipal Hospital, 1-1 Matoba, Tottori 680-8501, Japan

[6]Department of Medicine, Division of Metabolism and Biosystemic Science, Asahikawa Medical University, 1-1-1 Midorigaokahigashinijyo, Asahikawa 078-8510, Japan

关键词: Lymph node metastasis;    Tumourigenesis;    Thyroid carcinoma;    Localization;    PLZF;   

Others  :  863191
DOI  :  10.1186/1472-6823-14-52

 received in 2013-11-13, accepted in 2014-06-30,  发布年份 2014

【 摘 要 】

Background

Promyelocytic leukaemia zinc finger (PLZF) is a transcriptional repressor that was originally isolated from a patient with promyelocytic leukaemia. PLZF also affects key elements for cell cycle progression, such as cyclin A, and can affect the tumourigenicity of various cancers. Thus far, the behaviour of PLZF in thyroid carcinoma remains unclear.

Methods

We analysed the expression profile of PLZF in different types of benign and malignant thyroid lesions as well as in normal thyroid tissue. Specifically, we examined PLZF expression in normal thyroid (N; n = 4), adenomatous lesion (AL; n = 5), follicular adenoma (FA; n = 2), papillary thyroid carcinoma (PTC; n = 20), and anaplastic thyroid carcinoma (ATC; n = 3) samples. PLZF expression was estimated by western blotting and immunohistochemical (IHC) staining.

Results

PLZF was expressed in all samples of thyroid lesions examined. In N, AL, and FA, PLZF was mainly localized in the nucleus. In contrast, in PTC and ATC, PLZF was mainly expressed in the cytosol with high intensity. In more detail, the cytoplasmic IHC scores in PTC with capsular invasion (CI) and lymph node (LN) metastasis were higher than those in PTC without CI and LN metastasis.

Conclusions

PLZF shows different subcellular localizations among PTC, ATC, and other thyroid lesions. Furthermore, high cytoplasmic expression of PLZF may be correlated with CI and LN metastasis in thyroid carcinoma. The present report is the first to describe the implications of intracellular PLZF expression in thyroid carcinomas.

【 授权许可】

   
2014 Matsuzawa et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Davies L, Welch HG: Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006, 295:2164-2167.
• [2]Leenhardt L, Grosclaude P, Chérié-Challine L: Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 2004, 14:1056-1060.
• [3]Pilli T, Prasad KV, Jayarama S, Pacini F, Prabhakar BS: Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer. Thyroid 2009, 19:1333-1342.
• [4]Chen Z, Brand NJ, Chen A, Chen SJ, Tong JH, Wang ZY, Waxman S, Zelent A: Fusion between a novel Krüppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J 1993, 12:1161-1167.
• [5]Chen SJ, Zelent A, Tong JH, Yu HQ, Wang ZY, Derrè J, Berger R, Waxman S, Chen Z: Rearrangements of the retinoic acid receptor alpha and promyelocytic leukemia zinc finger genes resulting from t(11;17)(q23;q21) in a patient with acute promyelocytic leukemia. J Clin Invest 1993, 91:2260-2267.
• [6]Li JY, English MA, Ball HJ, Yeyati PL, Waxman S, Licht JD: Sequence-specific DNA binding and transcriptional regulation by the promyelocytic leukemia zinc finger protein. J Biol Chem 1997, 272:22447-22455.
• [7]Felicetti F, Bottero L, Felli N, Mattia G, Labbaye C, Alvino E, Peschle C, Colombo MP, Carè A: Role of PLZF in melanoma progression. Oncogene 2004, 23:4567-4576.
• [8]Cheung M, Pei J, Pei Y, Jhanwar SC, Pass HI, Testa JR: The promyelocytic leukemia zinc-finger gene, PLZF, is frequently downregulated in malignant mesothelioma cells and contributes to cell survival. Oncogene 2010, 29:1633-1640.
• [9]McConnell MJ, Chevallier N, Berkofsky-Fessler W, Giltnane JM, Malani RB, Staudt LM, Licht JD: Growth suppression by acute promyelocytic leukemia-associated protein PLZF is mediated by repression of c-myc expression. Mol Cell Biol 2003, 23:9375-9388.
• [10]Allred DC, Harvey JM, Berardo M, Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998, 11:155-168.
• [11]Zhang T, Xiong H, Kan LX, Zhang CK, Jiao XF, Fu G, Zhang QH, Lu L, Tong JH, Gu BW, Yu M, Liu JX, Licht J, Waxman S, Zelent A, Chen E, Chen SJ: Genomic sequence, structural organization, molecular evolution, and aberrant rearrangement of promyelocytic leukemia zinc finger gene. Proc Natl Acad Sci U S A 1999, 96:11422-11427.
• [12]Shaknovich R, Yeyati PL, Ivins S, Melnick A, Lempert C, Waxman S, Zelent A, Licht JD: The promyelocytic leukemia zinc finger protein affects myeloid cell growth, differentiation, and apoptosis. Mol Cell Biol 1998, 18:5533-5545.
• [13]Ward JO, McConnell MJ, Carlile GW, Pandolfi PP, Licht JD, Freedman LP: The acute promyelocytic leukemia-associated protein, promyelocytic leukemia zinc finger, regulates 1,25-dihydroxyvitamin D(3)-induced monocytic differentiation of U937 cells through a physical interaction with vitamin D(3) receptor. Blood 2001, 98:3290-3300.
• [14]Yeyati PL, Shaknovich R, Boterashvili S, Li J, Ball HJ, Waxman S, Nason-Burchenal K, Dmitrovsky E, Zelent A, Licht JD: Leukemia translocation protein PLZF inhibits cell growth and expression of cyclin A. Oncogene 1999, 18:925-934.
• [15]Doulatov S, Notta F, Rice KL, Howell L, Zelent A, Licht JD, Dick JE: PLZF is a regulator of homeostatic and cytokine-induced myeloid development. Genes Dev 2009, 23:2076-2087.
• [16]Nanba D, Mammoto A, Hashimoto K, Higashiyama S: Proteolytic release of the carboxy-terminal fragment or proHB-EGF causes nuclear export of PLZF. J Cell Biol 2003, 163:489-502.
• [17]Ota I, Higashiyama S, Masui T, Yane K, Hosoi H, Matsuura N: Heparin-binding EGF-like growth factor enhances the activity of invasion and metastasis in thyroid cancer cells. Oncol Rep 2013, 30:1593-1600.
• [18]Felli N, Flicetti F, Lustri AM, Errico MC, Bottero L, Cannistraci A, De Feo A, Petrini M, Pedini F, Biffoni M, Alvino E, Negrini M, Ferracin M, Matta G, Carè A: miR-126 and 126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma. PLoS One 2013, 8:e56824.
• [19]Ozeki K, Tanida S, Morimoto C, Inoue Y, Mizoshita T, Tsukamoto H, Shimura T, Kataoka H, Kamiya T, Nishiwaki E, Ishiguro H, Higashiyama S, Joh T: Telmisartan inhibits cell proliferation by blocking nuclear translocation of ProHB-EGF C-terminal fragment in colon cancer cells. PLoS One 2013, 8:e56770.